Mallinckrodt voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court to change its capital structure. The company expects to reduce its total debt by approximately $1.3 billion by restructuring its obligations under the procedure. Mallinckrodt and all its subsidiaries continue to operate and supply customers and patients with products as usual.